Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | PAM | P19021 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11048026 | 1.00 | HTR2A (0.48) | HTR2AIDO1PAMMAOBSIGMAR1 | |
| SCHEMBL9466771 | 0.83 | PAM (0.48) | HTR2AIDO1PAMMAOBSIGMAR1 | |
| SCHEMBL10746755 | 0.83 | PAM (0.48) | HTR2AIDO1PAMMAOBSIGMAR1 | |
| SCHEMBL6280401 | 0.81 | HTR2A (0.44) | HTR2AIDO1PAMMAOBSIGMAR1 | |
| SCHEMBL10520320 | 0.81 | TAAR1 (0.47) | HTR2AIDO1PAMMAOBSIGMAR1 | |
| SCHEMBL10520329 | 0.81 | TAAR1 (0.47) | HTR2AIDO1PAMMAOBSIGMAR1 | |
| SCHEMBL16707823 | 0.79 | PAM (0.46) | HTR2AIDO1PAMMAOBSIGMAR1 | |
| SCHEMBL9493231 | 0.79 | HTR2A (0.40) | HTR2AIDO1PAMMAOBSIGMAR1 | |
| SCHEMBL9493232 | 0.79 | HTR2A (0.40) | HTR2AIDO1PAMMAOBSIGMAR1 | |
| SCHEMBL7792765 | 0.79 | IDO1 (0.48) | HTR2AIDO1PAMMAOBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315210-A1 | ANTIVIRAL FIBERS, FABRICS AND FABRIC-BASED PRODUCTS | NOBIO LTD. (IL) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315210-A1 | ANTIVIRAL FIBERS, FABRICS AND FABRIC-BASED PRODUCTS | EIF2AK2, ZC3HAV1, MAVS | HTR2A 4490/4885IDO1 2584/4885PAM 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.